Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy

Cancer Treatment Reviews

Volumn 41, Issue 3, 2015, Pages 222-234

  Bizama, Carolina ^a   García, Patricia ^a   Espinoza, Jaime A ^a   Weber, Helga ^b   Leal, Pamela ^b   Nervi, Bruno ^a   Roa, Juan Carlos ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Directing rational cancer therapy; Gallbladder cancer; Genetic and epigenetic alterations; Intracellular pathways

Indexed keywords

ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GALLBLADDER CARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC DIFFERENCE; GEOGRAPHIC PATHOLOGY; HEDGEHOG; HETEROZYGOSITY LOSS; HUMAN; INTRACELLULAR SIGNALING; LONG TERM SURVIVAL; META ANALYSIS (TOPIC); MICROSATELLITE INSTABILITY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; ANIMAL; DRUG EFFECTS; GALLBLADDER NEOPLASMS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; GALLBLADDER NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84923202258     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.01.003     Document Type: Review

References (145)

1. J. Ferlay, I. Soerjomataram, M. Ervik, GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, 2013.
2. Andren-Sandberg A. Diagnosis and management of gallbladder cancer. N Am J Med Sci 2012, 4(7):293-299.
3. Compton C.C., Byrd D.R., Garcia-Aguilar J., Kurtzman S.H., Olawaiye A., Washington M.K. Gallbladder. AJCC cancer staging atlas 2012, 259-268. Springer, NY. 2nd ed.
4. Goldin R.D., Roa J.C. Gallbladder cancer: a morphological and molecular update. Histopathology 2009, 55(2):218-229.
5. Lim H., Seo D.W., Parkdo H., Lee S.S., Lee S.K., Kim M.H., et al. Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients. J Clin Gastroenterol 2013, 47(5):443-448.
6. Roa J.C., Tapia O., Manterola C., Villaseca M., Guzman P., Araya J.C., et al. Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor. Virchows Arch 2013, 463(5):651-661.
7. Shindoh J., de Aretxabala X., Aloia T.A., Roa J.C., Roa I., Zimmitti G., et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg 2014.
8. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
9. Fong Y., Wagman L., Gonen M., Crawford J., Reed W., Swanson R., et al. Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. Ann Surg 2006, 243(6):767-771. [discussion 771-4].
10. Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Maraveyas A., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362(14):1273-1281.
11. Valle J.W., Furuse J., Jitlal M., Beare S., Mizuno N., Wasan H., et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014, 25(2):391-398.
12. Bertran E., Heise K., Andia M.E., Ferreccio C. Gallbladder cancer: incidence and survival in a high-risk area of Chile. Int J Cancer 2010, 127(10):2446-2454.
13. Stinton L.M., Shaffer E.A. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012, 6(2):172-187.
14. Jain K., Mohapatra T., Das P., Misra M.C., Gupta S.D., Ghosh M., et al. Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer. Ann Surg 2014, 260(6):1073-1080.
15. Roa I., Ibacache G., Roa J., Araya J., de Aretxabala X., Munoz S. Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer: a case-control study. J Surg Oncol 2006, 93(8):624-628.
16. Wistuba I.I., Gazdar A.F. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004, 4(9):695-706.
17. Simbolo M., Fassan M., Ruzzenente A., Mafficini A., Wood L.D., Corbo V., et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 2014, 5(9):2839-2852.
18. Li M., Zhang Z., Li X., Ye J., Wu X., Tan Z., et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 2014.
19. Javle M., Rashid A., Churi C., Kar S., Zuo M., Eterovic A.K., et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol 2014, 45(4):701-708.
20. Yokoyama N., Hitomi J., Watanabe H., Ajioka Y., Pruyas M., Serra I., et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998, 7(4):297-301.
21. Nagahashi M., Ajioka Y., Lang I., Szentirmay Z., Kasler M., Nakadaira H., et al. Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. World J Gastroenterol 2008, 14(1):70-75.
22. Adsay V., Jang K.T., Roa J.C., Dursun N., Ohike N., Bagci P., et al. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are >/=1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol 2012, 36(9):1279-1301.
23. Trivedi V., Gumaste V.V., Liu S., Baum J. Gallbladder cancer: adenoma-carcinoma or dysplasia-carcinoma sequence?. Gastroenterol Hepatol (NY) 2008, 4(10):735-737.
24. Aldouri A.Q., Malik H.Z., Waytt J., Khan S., Ranganathan K., Kummaraganti S., et al. The risk of gallbladder cancer from polyps in a large multiethnic series. Eur J Surg Oncol 2009, 35(1):48-51.
25. Yokoyama N., Hitomi J., Watanabe H., Ajioka Y., Pruyas M., Serra I., et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998, 7(4):297-301.
26. Wistuba I.I., Miquel J.F., Gazdar A.F., Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999, 30(1):21-25.
27. Kang C.M., Kim K.S., Choi J.S., Lee W.J., Kim B.R. Gallbladder carcinoma associated with anomalous pancreaticobiliary duct junction. Can J Gastroenterol 2007, 21(6):383-387.
28. Maurya S.K., Tewari M., Mishra R.R., Shukla H.S. Genetic aberrations in gallbladder cancer. Surg Oncol 2012, 21(1):37-43.
29. Hanada K., Itoh M., Fujii K., Tsuchida A., Ooishi H., Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996, 77(3):452-458.
30. Hanada K., Tsuchida A., Iwao T., Eguchi N., Sasaki T., Morinaka K., et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999, 94(6):1638-1642.
31. Kumari N., Corless C.L., Warrick A., Beadling C., Nelson D., Neff T., et al. Mutation profiling in gallbladder cancer in Indian population. Indian J Pathol Microbiol 2014, 57(1):9-12.
32. Roa J.C., Anabalon L., Tapia O., Melo A., de Aretxabala X., Roa I. Frequency of K-ras mutation in biliary and pancreatic tumors. Rev Med Chil 2005, 133(12):1434-1440.
33. Li M., Zhang Z., Li X., Ye J., Wu X., Tan Z., et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 2014.
34. Wistuba I.I., Miquel J.F., Gazdar A.F., Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999, 30(1):21-25.
35. Pai R.K., Mojtahed K. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. Appl Immunohistochem Mol Morphol 2011, 19(2):133-140.
36. Ong C.K., Subimerb C., Pairojkul C., Wongkham S., Cutcutache I., Yu W., et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012, 44(6):690-693.
37. Chan-On W., Nairismagi M.L., Ong C.K., Lim W.K., Dima S., Pairojkul C., et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013, 45(12):1474-1478.
38. Ayoola A., Barochia A., Belani K., Belani C.P. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 2012, 30(5):433-446.
39. Barreto S.G., Dutt A., Chaudhary A. A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol 2014, 25(6):1086-1097.
40. Roa J., Adsay V. Molecular pathology of gallbladder cancer. Molecular surgical pathology 2013, 65-81. Springer, New York.
41. Jiao Y., Pawlik T.M., Anders R.A., Selaru F.M., Streppel M.M., Lucas D.J., et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013, 45(12):1470-1473.
42. Javle M., Rashid A., Churi C., Kar S., Zuo M., Eterovic A.K., et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol 2014, 45(4):701-708.
43. Moreno M., Pimentel F., Gazdar A.F., Wistuba I.I., Miquel J.F. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol 2005, 4(3):192-199.
44. Saetta A.A., Papanastasiou P., Michalopoulos N.V., Gigelou F., Korkolopoulou P., Bei T., et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004, 445(2):179-182.
45. Nakazawa K., Dobashi Y., Suzuki S., Fujii H., Takeda Y., Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005, 206(3):356-365.
46. Roa J.C., Roa I., Correa P., Vo Q., Araya J.C., Villaseca M., et al. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol 2005, 40(1):79-86.
47. Garcia P., Manterola C., Araya J.C., Villaseca M., Guzman P., Sanhueza A., et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog 2009, 48(1):79-89.
48. Letelier P., Garcia P., Leal P., Alvarez H., Ili C., Lopez J., et al. MiR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol 2014, 7(5):1849-1867.
49. Zhou H., Guo W., Zhao Y., Wang Y., Zha R., Ding J., et al. MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer Sci 2014, 105(8):956-965.
50. Zhou H., Guo W., Zhao Y., Wang Y., Zha R., Ding J., et al. MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. Int J Oncol 2014, 44(6):2050-2058.
51. Peng H.H., Zhang Y.D., Gong L.S., Liu W.D., Zhang Y. Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. Onco Targets Ther 2013, 6:1625-1630.
52. Fan H.X., Wang S., Zhao H., Liu N., Chen D., Sun M., et al. Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression. Med Oncol 2014, 31(7):41.
53. Ruch J.M., Kim E.J. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs 2013, 73(7):613-623.
54. Athar M., Li C., Kim A.L., Spiegelman V.S., Bickers D.R. Sonic hedgehog signaling in basal cell nevus syndrome. Cancer Res 2014, 74(18):4967-4975.
55. Nagao-Kitamoto H., Nagata M., Nagano S., Kitamoto S., Ishidou Y., Yamamoto T., et al. GLI2 is a novel therapeutic target for metastasis of osteosarcoma. Int J Cancer 2014.
56. Xie F., Xu X., Xu A., Liu C., Liang F., Xue M., et al. Aberrant activation of Sonic hedgehog signaling in chronic cholecystitis and gallbladder carcinoma. Hum Pathol 2014, 45(3):513-521.
57. Matsushita S., Onishi H., Nakano K., Nagamatsu I., Imaizumi A., Hattori M., et al. Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer. Cancer Sci 2014, 105(3):272-280.
58. Li J., Wu T., Lu J., Cao Y., Song N., Yang T., et al. Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma. Surg Today 2012, 42(8):770-775.
59. Desai M.D., Saroya B.S., Lockhart A.C. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin Investig Drugs 2013, 22(3):341-356.
60. Kiesslich T., Mayr C., Wachter J., Bach D., Fuereder J., Wagner A., et al. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem 2014.
61. Meiss F., Zeiser R. Vismodegib. Recent Results Cancer Res 2014, 201:405-417.
62. Berlin J., Bendell J.C., Hart L.L., Firdaus I., Gore I., Hermann R.C., et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 2013, 19(1):258-267.
63. Tremblay M.R., Lescarbeau A., Grogan M.J., Tan E., Lin G., Austad B.C., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009, 52(14):4400-4418.
64. Jimeno A., Weiss G.J., Miller W.H., Gettinger S., Eigl B.J., Chang A.L., et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 2013, 19(10):2766-2774.
65. D. Richards, A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer, 2012: 2012 Gastrointestinal Cancers Symposium. p. Suppl 4; abstr 213.
66. Ciuffreda L., Di Sanza C., Incani U.C., Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010, 10(5):484-495.
67. Deshpande V., Nduaguba A., Zimmerman S.M., Kehoe S.M., Macconaill L.E., Lauwers G.Y., et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011, 11:60.
68. Riener M.O., Bawohl M., Clavien P.A., Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosom Cancer 2008, 47(5):363-367.
69. Liu D.C., Yang Z.L. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 2011, 207(8):472-478.
70. Lunardi A., Webster K.A., Papa A., Padmani B., Clohessy J.G., Bronson R.T., et al. Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget 2014, 5(4):894-900.
71. Hansel D.E., Rahman A., Hidalgo M., Thuluvath P.J., Lillemoe K.D., Shulick R., et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 2003, 163(1):217-229.
72. Leal P., Garcia P., Sandoval A., Letelier P., Brebi P., Ili C., et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med 2013, 137(4):552-557.
73. Leal P., Garcia P., Sandoval A., Buchegger K., Weber H., Tapia O., et al. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 2013, 6:1373-1384.
74. Wu Q., Kiguchi K., Kawamoto T., Ajiki T., Traag J., Carbajal S., et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 2007, 67(8):3794-3800.
75. Lindsley C.W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 2010, 10(4):458-477.
76. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9(7):1956-1967.
77. Keck S., Glencer A.C., Rugo H.S. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncol 2012, 8(11):1383-1396.
78. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13(14):4261-4270.
79. Mabuchi S., Altomare D.A., Connolly D.C., Klein-Szanto A., Litwin S., Hoelzle M.K., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007, 67(6):2408-2413.
80. Tai S., Sun Y., Liu N., Ding B., Hsia E., Bhuta S., et al. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther 2012, 11(6):1320-1331.
81. Lim T., Lee J., Lee D.J., Lee H.Y., Han B., Baek K.K., et al. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 2011, 68(1):255-262.
82. Yoon D.H., Ryu M.H., Park Y.S., Lee H.J., Lee C., Ryoo B.Y., et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 2012, 106(6):1039-1044.
83. Lee S.J., Lee J., Lee J., Park S.H., Park J.O., Park Y.S., et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs 2013, 31(6):1580-1586.
84. Ohtsu A., Ajani J.A., Bai Y.X., Bang Y.J., Chung H.C., Pan H.M., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013, 31(31):3935-3943.
85. Altomare I., Hurwitz H. Everolimus in colorectal cancer. Expert Opin Pharmacother 2013, 14(4):505-513.
86. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011, 11(5):338-351.
87. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8(2):97-106.
88. Aster J.C., Blacklow S.C. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 2012, 30(19):2418-2420.
89. Nickoloff B.J., Osborne B.A., Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003, 22(42):6598-6608.
90. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27(38):5132-5137.
91. Li J.L., Harris A.L. Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 2005, 8(1):1-3.
92. Lobry C., Oh P., Mansour M.R., Look A.T., Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood 2014, 123(16):2451-2459.
93. Takebe N., Nguyen D., Yang S.X. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014, 141(2):140-149.
94. Lobry C., Oh P., Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011, 208(10):1931-1935.
95. Sekiya S., Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest 2012, 122(11):3914-3918.
96. El Khatib M., Bozko P., Palagani V., Malek N.P., Wilkens L., Plentz R.R. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS ONE 2013, 8(10):e77433.
97. Zender S., Nickeleit I., Wuestefeld T., Sorensen I., Dauch D., Bozko P., et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013, 23(6):784-795.
98. Yoon H.A., Noh M.H., Kim B.G., Han J.S., Jang J.S., Choi S.R., et al. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 2011, 17(35):4023-4030.
99. Tolcher A.W., Messersmith W.A., Mikulski S.M., Papadopoulos K.P., Kwak E.L., Gibbon D.G., et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 2012, 30(19):2348-2353.
100. Strosberg J.R., Yeatman T., Weber J., Coppola D., Schell M.J., Han G., et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012, 48(7):997-1003.
101. Sahebjam S., Bedard P.L., Castonguay V., Chen Z., Reedijk M., Liu G., et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer 2013, 109(4):943-949.
102. Diaz-Padilla I., Hirte H., Oza A.M., Clarke B.A., Cohen B., Reedjik M., et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs 2013, 31(5):1182-1191.
103. Krop I., Demuth T., Guthrie T., Wen P.Y., Mason W.P., Chinnaiyan P., et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012, 30(19):2307-2313.
104. Floyd D.H., Kefas B., Seleverstov O., Mykhaylyk O., Dominguez C., Comeau L., et al. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol 2012, 14(10):1215-1226.
105. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21(2):177-184.
106. Zhou Y.M., Li Y.M., Cao N., Feng Y., Zeng F. Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma. Ai Zheng 2003, 22(3):262-265.
107. Yoon J.H., Higuchi H., Werneburg N.W., Kaufmann S.H., Gores G.J. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002, 122(4):985-993.
108. Werneburg N.W., Yoon J.H., Higuchi H., Gores G.J. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2003, 285(1):G31-G36.
109. Harder J., Waiz O., Otto F., Geissler M., Olschewski M., Weinhold B., et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009, 15(36):4511-4517.
110. Roa I., de Toro G., Schalper K., de Aretxabala X., Churi C., Javle M. Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res 2014, 7(2):42-48.
111. Kawamoto T., Krishnamurthy S., Tarco E., Trivedi S., Wistuba I.I., Li D., et al. HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res 2007, 1(6):221-227.
112. Kalekou H., Miliaras D. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol 2004, 19(7):812-818.
113. Toledo C., Matus C.E., Barraza X., Arroyo P., Ehrenfeld P., Figueroa C.D., et al. Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol 2012, 18(11):1208-1215.
114. Kiguchi K., Carbajal S., Chan K., Beltran L., Ruffino L., Shen J., et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001, 61(19):6971-6976.
115. Gruenberger B., Schueller J., Heubrandtner U., Wrba F., Tamandl D., Kaczirek K., et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010, 11(12):1142-1148.
116. Malka D., Cervera P., Foulon S., Trarbach T., de la Fouchardiere C., Boucher E., et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014, 15(8):819-828.
117. Hezel A.F., Noel M.S., Allen J.N., Abrams T.A., Yurgelun M., Faris J.E., et al. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br J Cancer 2014, 111(3):430-436.
118. Lubner S.J., Mahoney M.R., Kolesar J.L., Loconte N.K., Kim G.P., Pitot H.C., et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010, 28(21):3491-3497.
119. Lee J., Park S.H., Chang H.M., Kim J.S., Choi H.J., Lee M.A., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012, 13(2):181-188.
120. Brechbiel J., Miller-Moslin K., Adjei A.A. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev 2014, 40(6):750-759.
121. Hezel A.F., Deshpande V., Zhu A.X. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010, 28(21):3531-3540.
122. Li Q., Yang Z. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 2009, 28:65.
123. Bengala C., Bertolini F., Malavasi N., Boni C., Aitini E., Dealis C., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010, 102(1):68-72.
124. El-Khoueiry A.B., Ramanathan R.K., Yang D.Y., Zhang W., Shibata S., Wright J.J., et al. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs 2012, 30(3):1175-1183.
125. El-Khoueiry A.B., Rankin C., Siegel A.B., Iqbal S., Gong I.Y., Micetich K.C., et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 2014, 110(4):882-887.
126. Lee J.K., Capanu M., O'Reilly E.M., Ma J., Chou J.F., Shia J., et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer 2013, 109(4):915-919.
127. Bekaii-Saab T., Phelps M.A., Li X., Saji M., Goff L., Kauh J.S., et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011, 29(17):2357-2363.
128. Akinleye A., Furqan M., Mukhi N., Ravella P., Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013, 6:27.
129. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3(6):401-410.
130. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
131. Jiang L., Chen Y.L., She F.F., Tang N.H., Li X.J., Wang X.X. Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma. Zhonghua Zhong Liu Za Zhi 2010, 32(3):190-195.
132. Letelier P., Garcia P., Leal P., Ili C., Buchegger K., Riquelme I., et al. Immunohistochemical expression of vascular endothelial growth factor a in advanced gallbladder carcinoma. Appl Immunohistochem Mol Morphol 2013.
133. Nakashima T., Kondoh S., Kitoh H., Ozawa H., Okita S., Harada T., et al. Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int J Mol Med 2003, 11(1):33-39.
134. Sun X.N., Cao W.G., Wang X., Wang Q., Gu B.X., Yang Q.C., et al. Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol 2011, 32(6):1183-1190.
135. Tian Y., Ding R.Y., Zhi Y.H., Guo R.X., Wu S.D. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006, 12(3):415-419.
136. Qiang D., Lei J., Xiaoqian W., Meiping W., Feifei S., Yanling C. TNF-alpha promotes the lymphangiogenesis of gallbladder carcinoma through NF-kappaB-mediated up-regulation of VEGF-C. Cancer Sci 2014.
137. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400.
138. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., Kambadakone A.R., Muzikansky A., Zheng H., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11(1):48-54.
139. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007, 5(3):203-220.
140. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10(8):537-549.
141. Porter J.R., Fritz C.C., Depew K.M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010, 14(3):412-420.
142. ClinicalTrials.gov, U.S. National Institutes of Health. 2014 [accessed 10.09.14]. http://www.clinicaltrials.gov.
143. NCT01425879, MK2206 in treating patients with advanced refractory biliary cancer that cannot be removed by surgery. 2014 [17.08.14].
144. Yi J.H., Thongprasert S., Lee J., Doval D.C., Park S.H., Park J.O., et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012, 48(2):196-201.
145. El-Khoueiry A.B., Rankin C.J., Ben-Josef E., Lenz H.J., Gold P.J., Hamilton R.D., et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 2012, 30(4):1646-1651.